Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves by Dumka, Vinod K. & Srivastava, Anil K.
JOURNAL OF
Veterinary 
Science
J. Vet. Sci. (2006), 7(4), 333–337
Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin 
following a single intramuscular administration in cross bred calves
Vinod K. Dumka
1,*, Anil K. Srivastava
2
1Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Science 
University, Ludhiana-141004, India
2Faculty of Veterinary Science and Animal Husbandry, Sher-e-Kashmir University of Agricultural Science and Technology, R S 
Pura, Jammu-181102, India
The pharmacokinetics and urinary excretion following
single intramuscular administration of levofloxacin at a
dose of 4 mg/kg was investigated in seven male cross bred
calves. Appreciable plasma concentration of levofloxacin
(0.38 ± 0.06 µg/ml) was detected at 1 min after injection
and the peak plasma level of 3.07 ± 0.08 µg/ml was
observed at 1 h. The drug level above MIC 90 in plasma
was detected up to 12 h after administration. Rapid
absorption of the drug was also evident by the high value
of the absorption rate constant (2.14 ± 0.24 /h). The overall
systemic bioavailability of levofloxacin, after intramuscular
administration, was 56.6 ± 12.4%. The high value of AUC
(7.66 ± 0.72 mg . h/ml) reflected the vast area of body
covered by drug concentration. Extensive distribution of
the drug into various body fluids and tissues was noted by
the high value of Vdarea (1.02 ± 0.05 l/kg). The high ratio of
AUC/MIC (76.6 ± 7.25) obtained in this study indicated
excellent clinical and bacteriological efficacy of levofloxacin
in calves. The elimination half-life and MRT were 3.67 ±
0.4 h and 5.57 ± 0.51 h, respectively. The total body clearance
(ClB) was 204.9 ± 22.6 ml/kg/h. On the basis of the
pharmacokinetic parameters, a suitable intramuscular
dosage regimen for levofloxacin in calves would be 1.5 mg/
kg repeated at 12 h intervals.
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Introduction
Fluoroquinolone resistance relates directly to human and
veterinary usage; emerging bacterial resistance poses the single
greatest threat to the future survival of the fluoroquinolone
drugs as an effective antibiotic class [6]. Levofloxacin [(-)-
9-Fluoro-3-methyl-10-(4-methyl-1-piprazinyl)-7-oxo-2,3-
dihydro-7H-pyrido [1,2,3-de] [1,4]-benzoxazine-6-carboxylic
acid] a recently introduced second generation fluoroquinolone,
possesses excellent activity against gram-positive, gram-
negative and anaerobic bacteria [8,17]. As compared to other
fluoroquinolones, ofloxacin and ciprofloxacin, it also has
more pronounced bactericidal activity against organisms
like Pseudomonas, Enterobacteriaceae and Klebsiella [15].
The drug is well distributed to target body tissues and fluids
in the respiratory tract, skin, urine and prostrate; in addition,
its uptake by cells makes it suitable for use against
intracellular pathogens [16]. Levofloxacin is metabolized in
the liver to demethyl-levofloxacin and levofloxacin-N-oxide
and excreted in the urine [16]. The pharmacokinetics of
levofloxacin has been investigated in man [7] and guinea
pigs [9]. However, information on the pharmacokinetics of
levofloxacin in cattle is completely lacking. In view of the
marked species variation in the kinetic data of antimicrobial
drugs, the present study was undertaken to determine the
pharmacokinetics, urinary excretion and an appropriate
dosage regimen, following single intramuscular administration
and in vitro plasma protein binding of levofloxacin in cross
bred calves.
Materials and Methods
Animals and drug administration
Seven healthy male cross bred calves (Holstein Friesian ×
Sahiwal), ranging between 1-1.5 years of age with an
average body weight of 87.3 ± 10.6 kg were used for this
study. The animals were maintained on seasonal green
fodder, wheat straw and water ad libitum. The average day
temperature in the shed was about 25
oC during the
experimental period. The experimental protocol followed
the ethical guidelines on the proper care and use of animals.
Levofloxacin (Hoechst Marion Roussel, India) was administered
intramuscularly at the dose rate of 4 mg/kg body weight into
the neck region.
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Collection of samples
To conduct the pharmacokinetic study, the animals were
kept in metabolic stalls of standard size, designed in such a
way that the entire amount of urine excreted naturally by the
animals within a period of time was automatically collected
without contamination or spillage in the containers placed
beneath the stalls. Blood samples (5 ml) were withdrawn
from the jugular vein into heparinized glass centrifuge tubes
before and at 1, 2.5, 5, 7.5, 10, 15, 20, 30, 45 min and 1, 1.5,
2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 h after administration of
the drug. Plasma was separated by centrifugation at 2,000
× g for 15 min at room temperature and kept at −20
oC until
analysis, which was done usually on the day of specimen
collection. Urine samples were also collected simultaneously
from the same animals at various predetermined time intervals
of 2, 4, 6, 8, 10, 12, 16 and 24 h after administration of the
drug. At the end of the given time interval, the volume of
total urine voided and colleted in the container, was
measured for each animal and after filtration, 10 ml samples
were taken for analysis.
Estimation of drug
The concentration of levofloxacin in plasma and urine
samples was estimated by a standard microbiological assay
technique [3] using Escherichia coli (ATCC 10536) as the
test organism. This method estimated the level of drug
having antibacterial activity, without differentiating between
the parent drug and its active metabolites. The assay could
detect a minimum of 0.1 µg/ml of levofloxacin. For each
sample, nine replicates were analyzed and corrected for the
zone of inhibition by standard reference solution. The standard
curve of levofloxacin is given in Fig. 1. The concentrations
of levofloxacin in the samples were calculated as µg/ml of
plasma or urine.
In vitro plasma protein binding
In vitro binding of levofloxacin to the plasma protein of
calves was determined by employing the equilibrium
dialysis technique [15] at plasma concentrations of 2, 5, 10,
20, 50 and 100 µg/ml and the constants for protein binding
were obtained.
Pharmacokinetic variables and dosage regimen
The plasma concentration-time profile of levofloxacin
after intramuscular administration in each animal was used
to establish various pharmacokinetic determinants and mean
kinetic variables were obtained by averaging the variables
calculated for individual animals. Overall systemic bioavailability
was calculated by using the values of the area under the
plasma concentration-time curve (AUC) and β obtained
after single intravenous administration of levofloxacin in the
same animals used for intramuscular study of levofloxacin
at an interval of 30 days. Pharmacokinetic parameters were
calculated manually by the computed least-squares linear
regression technique [10]. The maintenance (D') dose of
levofloxacin was calculated according to the equation:
D' = Cp(min)
∝ · Vd (e
βτ − 1).
The priming dose was obtained by omitting -1 from the
above equation. The Cp (min)
∝ is the minimum therapeutic
concentration of levofloxacin, the β is the elimination rate
constant and τ is the dosing interval [5].
Results
The mean plasma levels of levofloxacin at different time
intervals following a single intramuscular injection with a dose
of 4 mg/kg body weight are presented on a semilogarithmic
scale in Fig. 2. Intramuscular injection resulted into appreciable
plasma concentration of the drug (0.38 ± 0.06 µg/ml) at
1 min and a peak plasma level of 3.07 ± 0.08 µg/ml
 was
attained at 1 h post administration. The plasma levels then
declined gradually to 0.16 µg/ml
 at 12 h. Evaluation of the
results revealed that the disposition pattern of levofloxacin
followed a one-compartment open model that was adequately
described by the equation: Cp = Be
−βt − A'e
−Kat where, Cp is
the plasma level of levofloxacin at time t and e represents
the base of natural logarithm, A' and B are the extrapolated
zero-time intercepts of the absorption and elimination
phases, respectively, Ka and β are the absorption and
elimination rate constants, respectively. Table 1 shows the
pharmacokinetic parameters that describe the absorption
and elimination pattern of levofloxacin in the calves. A
graphical representation of the mean urine concentration of
levofloxacin along with cumulative per cent of drug excreted
in urine at different time intervals is shown in Fig. 3.
Fig. 1. Standard curve of levofloxacin in plasma of cross bred
calves. Each point represents the mean of the results from 14 assays.Pharmacokinetics of levofloxacin in calves 335
Discussion
The rapid appearance of levofloxacin in plasma following
its intramuscular administration suggested that the drug
rapidly entered into the systemic circulation. The high value
for the absorption rate constant further confirmed rapid
absorption of levofloxacin. Rapid absorption after intramuscular
injection has also been reported for other fluoroquinolones,
marbofloxacin [18,19] and ciprofloxacin [21] in cattle. An
average plasma concentration of 0.032-0.5 µg/ml has been
reported to be the minimum therapeutic concentration
(MIC90) of levofloxacin against most gram positive, gram
negative and atypical bacteria [7]. Keeping in mind the
synergistic effects of the immune system and other in vivo
factors, and to cover most of the susceptible organisms, in
this discussion, the MIC90 of 0.1 µg/ml of levofloxacin has
been taken into consideration. The peak plasma level of
levofloxacin attained in the present study was approximately
30 fold higher than the MIC of levofloxacin and the drug
was detected above the minimum therapeutic plasma level
up to 12 h of administration. Similar to our findings, a peak
plasma concentration of 3.4 µg/ml was attained after single
intraperitoneal injection of levofloxacin in pneumonic
guinea pigs [9]. The high value of AUC (7.66 ± 0.72 µg · h/
ml) and apparent volume of distribution (1.02 ± 0.05 l/kg)
obtained in the present study reflected the vast body area
covered by the drug concentration and extensive penetration
of levofloxacin into various body fluids and tissues after
intramuscular injection.
These observations are in accordance with the similar
values of AUC of marbofloxacin (7.648 mg · h/ml ) in cows
[18] and the high Vdarea of danofloxacin in goats [1] reported
after intramuscular injection. The high value of AUC/MIC 90
(76.6 ± 7.25) and Cmax/MIC90 (31.1 ± 0.82) obtained in the
present study, provides support for excellent clinical and
bacteriological efficacy of levofloxacin in calves. High
values of AUC/MIC have also been reported for other
fluoroquinolones. After intramuscular injection the AUC/
MIC ratio was 40.7 for marbofloxacin in cows [18] and 55.9
for danofloxacin in sheep [20]. In agreement with the present
results, a Cmax/MIC ratio of more than 10 has been reported
following subcutaneous administration of both danofloxacin
and enrofloxacin in calves [22]. The total body clearance of
levofloxacin in the present study was 204.9 ± 22.6 ml/kg/h
Table 1. Pharmacokinetic parameters of levofloxacin in cross
bred calves following single intramuscular administration (n = 7)
Parameter Unit Mean ± SE
A' µg/ml  1.27 ± 0.46
Ka /h  2.14 ± 0.24
t½Ka h  0.35 ± 0.03
B µg/ml  1.85 ± 0.43
β /h  0.204 ± 0.024
t1/2β h  3.67 ± 0.40
AUC µg . h/ ml  7.66 ± 0.72
AUMC µg . h
2/ml  40.5 ± 0.87
Vd(area) l/kg  1.02 ± 0.05
ClB ml/kg/h  204.9 ± 22.60
MRT h  5.57 ± 0.51
td h  19.5 ± 2.13
Cmax µg/ml  3.07 ± 0.08
Tmax h  1.00 ± 0.00
F %  56.6 ± 12.4
AUC/MIC ratio  76.6 ± 7.25
Cmax/MIC ratio  31.1 ± 0.82
A' and B: zero-time plasma drug concentration intercepts of the
regression lines of absorption and elimination phases, respectively; Ka
and  β: absorption and elimination rate constants, respectively; t ½Ka:
absorption half-life; t ½β: elimination half-life; AUC; area under the
plasma concentration-time curve; AUMC: area under the first moment
curve; Vdarea: apparent volume of distribution; Cl B: total body clearance;
MRT: mean residence time; td: duration of therapeutic effect; C max and
tmax: peak plasma drug concentration and time required to attain the peak
concentration, respectively; MIC: minimum inhibitory concentration of
drug in plasma; F: overall systemic bioavailability.
Fig. 2. Semilogarithmic plot of plasma concentration-time profil e
of levofloxacin following its single intramuscular injection of 4
mg/kg b.w. in cross bred calves. Values are presented as mean ±
SE (n = 7). The data were analyzed according to the one-
compartment open model. Absorption and elimination phases are
represented by least square regression lines. The calculate d
points (o) of distribution phases were obtained by residual
technique. Constants A' and B are zero-time intercepts o f
absorption and elimination phases, respectively. 336 Vinod K. Dumka, Anil K. Srivastava
and the elimination half-life (3.67 ± 0.4 h) was comparable
to the t½β of 2.53 h for marbofloxacin [18] and 2.4 h for
norfloxacin [12] in cattle and 4.41 h for danofloxacin in
goats [1] observed after intramuscular administration. Among
various pharmacokinetic parameters, bioavailability plays an
important role in the therapeutic efficacy of a drug. On the
basis of AUC and β after single intravenous (10.5 ± 0.2
µg · h/ml and 0.288 ± 0.001 /h, respectively) and intramuscular
(Table 1) administration in calves, the systemic bioavailability
of levofloxacin was calculated to be 56.6 ± 12.4% in the
calves. This finding was greater than the systemic
bioavailability of ciprofloxacin (21.6%) but lower the value
of 73% for norfloxacin and 91% for danofloxacin reported
after their intramuscular administration in cattle [2,12,21].
The concentration of levofloxacin-equivalent inhibitory
units in the urine was very high, at 36 times the MIC 90
(minimum inhibitory concentration) even 24 h after
administration. High urinary concentration of danofloxacin
(58.58 µg/ml) has also been reported after intravenous doses
of 1.25 mg/kg in goats [4]. Approximately 26.6% of the
microbiological activity of the administered drug was
recovered in the urine of calves within 24 h. These findings
suggest that levofloxacin may be an appropriate drug for
treating urinary tract infections in cattle. The extent of
binding of levofloxacin to the plasma proteins of calves
(17.0 ± 1.2%) in the present study was in accordance to the
corresponding values of 24-38% for levofloxacin in man
[16] and 26% for danofloxacin [11] and 36-45% for
enrofloxacin [13] in cattle. On the basis of the present study,
the priming and maintenance doses of levofloxacin, at a
dosage interval of 12 h, were calculated to be 1.48 and 1.38
mg/kg, respectively, or under field conditions, for most
bacteria sensitive to levofloxacin, the most appropriate
dosage regimen for levofloxacin, would be 1.5 mg/kg
repeated at 12 h intervals for the treatment of respiratory,
gastrointestinal, urinary tract and other infections in calves.
Lack of local reaction or any other adverse effect, rapid
absorption, moderate bioavailability, large volume of
distribution and high urinary concentration of levofloxacin
observed in the present study demonstrated that levofloxacin
may be effectively employed by the intramuscular route for
the treatment of bacterial infections in calves.
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